(Reuters) – The U.S. health regulator said on Tuesday GlaxoSmithKline and Vir Biotechnology’s drug sotrovimab was no longer authorized to treat COVID-19 in the U.S. due to an increase in the proportion of cases caused by the Omicron BA.2 sub-variant. (Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)